



Kalm Therapeutics Hires Dr. Tacey Viegas as Chief Development Officer

Huntsville, AL – Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tacey Viegas, B.Pharm., Ph.D., as Chief Development Officer. Dr. Viegas will oversee the product and preclinical development of the Kalm Patch, providing clinical and regulatory leadership for Kalm’s pipeline of products.

"I am excited to join Kalm’s experienced leadership team to develop the Kalm Patch for patients who are seeking better treatment options for managing atopic dermatitis. This innovation will help patients achieve a better quality of skin health," said Dr. Tacey Viegas.

Before joining Kalm, Dr. Viegas served as Chief Operating Officer at Serina Therapeutics for 18 years, leading early development efforts in CMC and preclinical safety and efficacy. He held various management roles at Nektar Therapeutics, where he co-invented nalexogol (Movantik®) and etirinotecan pegol (Onzeald™). At BioCryst Pharmaceuticals, he contributed to the early development of peramivir (Rapivab™), and at MDV Technologies, he invented and developed FloGel™ for treating burns, bruises, and abrasions. Movantik® was licensed to AstraZeneca in a \$1 billion deal, Onzeald™ to Daiichi Sankyo Europe for \$60 million plus royalties, and FloGel™ was acquired by Alliance Pharmaceuticals.

"Dr. Viegas is a seasoned and well-respected professional in the pharmaceutical industry," said Chris Seibert, CEO of Kalm Therapeutics, "His experience of leading multiple programs into the clinic is an asset to our company, as we prepare to build our Kalm Patch platform. We are thrilled and very fortunate to have someone with his credentials on our team."

Dr. Viegas serves on the scientific advisory committee of the National Institutes for Health (NIH-NIDA) and on numerous publication and scientific advisory committees within various professional organizations. He has over 50 patents issued, of which 10 are in the area of skin health treatment.

Kalm Therapeutics, Inc.:

Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. We offer a steroid-free, natural alternative to the growing number of adults and children battling eczema.

Media Contact:

Chris Seibert

chriseibert@kalmtherapeutics.com

www.kalmtherapeutics.com